about
Theranostic applications of antibodies in oncology.Solitary fibrous tumor - clinicopathologic, immunohistochemical and molecular analysis of 28 cases.The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcomaNext generation sequencing in synovial sarcoma reveals novel gene mutations.Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: the road ahead.Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.Anti-angiogenic therapy, a new player in the field of sarcoma treatment.Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes.Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.αB-crystallin expression is correlated with phospho-ERK1/2 expression in human breast cancer.IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization.Expression and clinical relevance of MET and ALK in Ewing sarcomas.Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.High prevalence of late adverse events in malignant bone tumour survivors diagnosed at adult age.Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.Hypoxia regulation of phosphokinases and the prognostic value of pAKT in breast cancer.Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.Targeting angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare diseaseNon-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside.Targeted therapy for Ewing's sarcoma: significance of heterogeneityTargeted Therapy-based Combination Treatment in RhabdomyosarcomaThe IGF pathway is activated in insulinomas but downregulated in metastatic diseaseDNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas
P50
Q27693293-75913B2C-B895-41AF-AA66-C7BBEF33ED11Q33418926-8F24706D-08DC-4F9E-A5E7-2F3D565D18D6Q35149569-1C78D233-D7CE-4175-8C69-894EC00DF85BQ36544186-4FC196B3-6738-4B11-A7AF-848494A6C7FEQ37150456-E8D0976A-E7EF-4827-A093-BFD4DB7C638DQ37908635-62717B68-BE7B-4B13-8E59-FCDD008BED97Q38192332-B45123D0-688E-46EB-98A8-94659076453BQ38194758-376E58DB-5888-4990-9EEA-612914FF5EEBQ38699597-A3457780-48EF-4E41-81EF-F0535AF3EE93Q39000880-86EA13A6-1DFF-41CA-85D5-7DB4D7A5B51EQ39124096-3AA1E371-AFA6-4E59-80FD-CA50064FD985Q39145671-D27DFD11-F8D8-4483-A368-3FF7CD434CF8Q39326887-767EACDF-0BDF-4764-A457-2AED7BE738F1Q39482081-8DDE9DAD-466A-4544-A23D-25C093169AB6Q39673956-8C3C5F22-E03B-4C90-BAAE-345F6BF46397Q41537706-7318A65C-9765-4809-8C1B-31B72F1C758CQ42378536-C19D7C77-D6DD-41EB-9D87-96D4D978FD92Q43437377-99826F67-75B1-4D9F-967D-A0B6C4B8C7DCQ47164935-FD491B1B-E0FF-46D7-A4B1-C00E86CF1F79Q64039304-BA949FD2-4173-40E8-954A-3E35857BF44FQ64972146-1B5AD40D-3B7B-4F02-B16F-3D83A8775C6AQ85190053-E1B33139-76DC-449C-A396-BD8ACA0F7F75Q89393262-8937A6A0-9FBA-4C09-B8C6-6CF331530B11Q90321148-E4A1ABB6-7A82-457A-A9D7-CA42D988FFE9Q90339021-1CEDABFE-5452-4B0B-818C-98BEB87A9866
P50
description
investigador
@es
researcher
@en
name
Yvonne M H Versleijen-Jonkers
@en
type
label
Yvonne M H Versleijen-Jonkers
@en
prefLabel
Yvonne M H Versleijen-Jonkers
@en
P108
P31
P496
0000-0001-7623-0505